The Phase I single ascending dose (SAD) and multiple ascending dose (MAD) trial (EUCT-2023-507910-28-00) found ARV-102, a proteolysis targeting chimaera (PROTAC) therapy, led to a drop in leucine ...

State Key Laboratory of Anti-Infective Drug Discovery and Development, Sun Yat-sen University, Guangzhou 510006, China Guangdong Provincial Key Laboratory of Chiral Molecules and Drug Discovery, ...

Bavdegalutamide (ARV-110) is a PROteolysis TArgeting Chimera (PROTAC) protein degrader that recruits the cereblon-containing E3 ubiquitin ligase to direct the polyubiquitination and subsequent ...

Introduction: Monensin resistance in Eimeria tenella poses a significant challenge in poultry farming, compromising the effectiveness of this widely used anticoccidial drug. The present study aimed to ...

Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 ...

NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein ...

Psilocybin is a hallucinogenic chemical in certain mushrooms known as magic mushrooms. Eating mushrooms that contain psilocybin can have a variety of effects, ranging from euphoria to ...

1 Vepdegestrant is a novel oral PROteolysis Targeting Chimera (PROTAC) ER degrader co-developed by Arvinas and Pfizer. In February 2024, the FDA granted Fast Track designation (FTD) to vepdegestrant ...

This study provides important insights into the regulation of type-I interferon signaling and anti-tumor immunity, demonstrating that ORMDL3 promotes RIG-I degradation to suppress immune responses.

Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, PR China Hunan Key Laboratory of Diagnostic and Therapeutic Drug Research for Chronic Diseases, Central South ...